Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ESR1 | P03372 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | STS | P08842 | 6/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379646 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL1977976 | 0.85 | HSD17B1 (0.46) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL12379647 | 0.85 | HSD17B1 (0.46) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL2293877 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL12379638 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL10116930 | 0.82 | STS (0.72) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| Estrone Acetate SCHEMBL20006536 | 0.80 | CYP3A4 (0.76) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| Estrone Acetate SCHEMBL603954 | 0.80 | CYP3A4 (0.76) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| Estrone Acetate SCHEMBL6241050 | 0.80 | CYP3A4 (0.76) | SMN1; SMN2ESR1LMNAADORA3ATM | |
| SCHEMBL11318628 | 0.79 | LMNA (0.67) | SMN1; SMN2ESR1LMNAPGRSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-2336146-A1 | 17beta-hydroxysteroid dehydrogenase inhibitors | Sterix Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20060074060-A1 | Compound | STERIX LIMITED (GB) | 2006-04-06 | — | — | US | disclosed |
| EP-1631579-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004085457-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074060-A1 | Compound | HAT1, CBR3, ADH5 | SMN1; SMN2 3055/4885ESR1 2958/4885LMNA 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.